ESMO Congress

Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.

The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.

Adding pembrolizumab to chemotherapy reduced the risk for disease recurrence, progression, complications, or death compared with chemotherapy alone in the treatment of triple-negative breast cancer.

The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.

Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

Tarlatamab 10 mg showed responses in patients with previously treated small cell lung cancer, and no new safety signals were observed.

Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.

Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.

With encouraging overall response and disease control rates, lenvatinib plus pembrolizumab has the potential to be a frontline treatment option for non–clear cell renal cell carcinoma.

Data presented at ESMO 2022 showed GSK3326595, aPRMT5 inhibitor, to display efficacy and safety signals consistent with those that were previously reported in advanced solid tumors.

Ribociclib combined with endocrine therapy adds survival benefit when given to patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases.

The use of adagrasib in combination with cetuximab or alone elicted encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.

Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.

The combination of belzutifan and cabozantanib maintained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

The combination of enfortumab vedotin plus pembrolizumab led to a confirmed overall response rate of 64.5% in patients with metastatic urothelial cancer.

A presentation at ESMO 2022 explains the use of circulating tumor DNA as a tool which can predict outcomes for patients with diffuse large B-cell lymphoma.

The combination of orelabrutinib plus the R-CHOP regimen revealed a positive overall response rate of 86.4% when given to patients with non-germinal center B cell-like diffuse large B-cell lymphoma.

Patients with more than 2 tertiary lymphoid structures, high Ki-67, and PD-1 positivity had high response rates to nivolumab plus ipilimumab.

No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.

The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.

Tucatinib alone and with trastuzumab supported further investigation of each regimen in metastatic HER2-positive colorectal cancer.

The rate of 2-year overall survival was nearly doubled with atezolizumab vs vinorelbine or gemcitabine in advanced platinum-ineligible non–small cell lung cancer.

A reduced the risk for disease progression by 27% was seen with the combination of cabozantinib added to nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma.